Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Mediastinal B Cell Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (1037
)
Diffuse Large B Cell Lymphoma (374
)
Mantle Cell Lymphoma (125
)
T Cell Non-Hodgkin Lymphoma (118
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (41
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (19
)
Non-Hodgkin’s Lymphoma (1037
)
Diffuse Large B Cell Lymphoma (374
)
Mantle Cell Lymphoma (125
)
T Cell Non-Hodgkin Lymphoma (118
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (41
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (19
)
›
Associations
(10)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
epcoritamab-bysp
Sensitive: A1 - Approval
epcoritamab-bysp
Sensitive
:
A1
epcoritamab-bysp
Sensitive: A1 - Approval
epcoritamab-bysp
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
IMPT-314
Sensitive: B - Late Trials
IMPT-314
Sensitive
:
B
IMPT-314
Sensitive: B - Late Trials
IMPT-314
Sensitive
:
B
MYC overexpression
Mediastinal B Cell Lymphoma
MYC overexpression
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Resistant: C3 – Early Trials
lisocabtagene maraleucel
Resistant
:
C3
lisocabtagene maraleucel
Resistant: C3 – Early Trials
lisocabtagene maraleucel
Resistant
:
C3
EZH2 overexpression
Mediastinal B Cell Lymphoma
EZH2 overexpression
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Resistant: C3 – Early Trials
lisocabtagene maraleucel
Resistant
:
C3
lisocabtagene maraleucel
Resistant: C3 – Early Trials
lisocabtagene maraleucel
Resistant
:
C3
MYC rearrangement
Mediastinal B Cell Lymphoma
MYC rearrangement
Mediastinal B Cell Lymphoma
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
BCL6 rearrangement
Mediastinal B Cell Lymphoma
BCL6 rearrangement
Mediastinal B Cell Lymphoma
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login